Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Exploratory Clinical Study of Orelabrutinib, Pomalidomide, Rituximab Combined With miniCHOP-like Regimen in Treatment-naive Elderly Patients With DLBCL

Next Previous
Trial Profile

Prospective Exploratory Clinical Study of Orelabrutinib, Pomalidomide, Rituximab Combined With miniCHOP-like Regimen in Treatment-naive Elderly Patients With DLBCL

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Orelabrutinib (Primary) ; Pomalidomide (Primary) ; Rituximab (Primary) ; Vindesine (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 13 Jun 2025 According to Innocare Pharma media release, the data from this trial has been presented at the European Hematology Association (EHA) 2025 Congress.
  • 13 Jun 2025 Results(n=32) presented in the Innocare Pharma media release.
  • 14 Apr 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top